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Assessing proliferation, cell-cycle arrest and apoptotic end points
in human buccal punch biopsies for use as pharmacodynamic
biomarkers in drug development
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1Edinburgh Cancer Centre, Western General Hospital, Edinburgh EH4 2XU, UK; 2University Dental Hospital of Manchester, Manchester M15 6FH, UK;
3AstraZeneca, Alderley Park, Macclesf ield, Cheshire SK10 4TG, UK
Easily accessible normal tissues expressing the same molecular site(s) of drug action as malignant tissue offer an enhanced potential
for early proof of anticancer drug mechanism and estimation of the biologically effective dose. Studies were undertaken in healthy
male volunteers to assess the tolerability of single and multiple (four in 24 h) 3 mm punch biopsies of the buccal mucosa, and to
determine the feasibility of detecting and quantifying a range of proliferation, cell-cycle arrest and apoptosis markers by
immunohistochemistry (IHC) for use as potential pharmacodynamic (PD) end points. The biopsy procedure was well tolerated with
100% of volunteers stating that they would undergo single (n¼ 10) and multiple (n¼ 12) biopsies again. Total retinoblastoma protein
(pRb), phosphorylated pRb (phospho-pRb), total p27, phosphorylated p27 (phospho-p27), phosphorylated-histone H3 (phospho-
HH3), p21, p53, Cyclin A, Cyclin E, Ki67 all produced good signal detection, but M30, cleaved caspase 3 and terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling did not. Total pRb, phospho-pRb, total p27 and phospho-p27
were quantified further in a multiple biopsy study to allow components of variability to be addressed to inform future sizing decisions
on intervention studies. Neither site of biopsy within the oral cavity, nor the nominal time of biopsy had any significant impact on any
of the four markers expression levels. Inter- and intrasubject coefficients of variation (CVs) that could be used to size future
intervention studies for pRb, phospho-pRb, total p27 and phospho-p27 were 14, 19, 18 and 16%; and 18, 29, 25 and 19%,
respectively. In conclusion, quantitation of such markers in 3 mm buccal punch biopsies would be suitable to explore as PD end points
within intervention studies of drugs acting on these pathways.
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Linking the molecular effects of drug exposure to the mechanisms
of either efficacy or toxicity of the drug would improve early
oncology drug development. While pharmacodynamic (PD) effects
derived directly from diseased/dysfuntional tissue are likely to
relate most closely to clinically relevant outcomes (Baselga, 2003),
tissue heterogeneity and tissue accessibility may restrict this
approach. PD biomarkers in relatively homogenous, more
accessible normal tissues may offer an easier approach to
establishing proof of drug mechanism and to make an early
assessment of exposure –response relationships.
Normal tissue-based PD approaches have already been used
with success during the clinical development of anticancer drugs
acting on biomarkers present within peripheral blood mono-
nuclear cells (Cohen et al, 2003; Peralba et al, 2003), exfoliated
buccal squames (van de Vaart et al, 2000; Adjei et al, 2003) and
punch biopsies of the skin (Albanell et al, 2002; Malik et al, 2003;
Vanhoefer et al, 2004). The choice of normal tissue for a given
drug study is likely to depend on a number of different factors,
including the level and variability of expression of the biomarker
of interest. Literature reports suggest that the buccal mucosa has a
high baseline proliferation index (Jordan et al, 1998; Hirota et al,
2002; Kurokawa et al, 2003), making it a potentially attractive
tissue for assessing antiproliferative end points. Unfortunately,
these indices are often obtained from individuals undergoing
follow up for various oral pathologies, therefore field effects
skewing these ‘normal’ values cannot be ruled out. In addition,
there are few published details on the tolerability of repeated
buccal biopsies as would be required during time-course PD
assessments, or of the baseline variability components of key
biomarkers to inform sizing decisions for drug intervention
studies designed to impact these markers.
MATERIALS AND METHODS
Study design and healthy volunteer recruitment
Two separate open nonrandomised buccal biopsy studies (Study A
and Study B) involving 10 and 12 healthy male volunteers,
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respectively, were approved by an independent ethics committee
and conducted in full accordance with the Declaration of Helsinki
and the International Committee on Harmonisation’s guidelines
on Good Clinical Practice. Study-specific exclusion criteria
included the use of tobacco-based products within 1 year of the
start of the study.
Study A was designed to address the tolerability, in practice,
of performing single buccal biopsies; the tolerability, in theory, of
performing multiple buccal biopsies; and the feasibility of
measuring a range of different proliferation, cell-cycle arrest and
apoptotic biomarkers in buccal biopsy specimens by immunohisto-
chemistry (IHC). Study B was designed to address the tolerability
of multiple buccal biopsies in practice and the variability
components of four key biomarkers. The volunteers underwent a
single buccal biopsy in Study A and four separate buccal biopsy
procedures over a 24-h period in Study B. The timings of biopsies
for each subject were expressed as both actual timings according to
the 24-h clock and as nominal timings (4, 8 and 24 h) relative to the
timing of the first biopsy (0 h).
The volunteers returned 24 h (730 min) post-completion of all
biopsy procedures (Study A), and again at 14 days (72 days)
(Studies A and B) for tolerability assessments and inspection of the
biopsy site(s). Any adverse events reported by the subjects were
graded according to the National Cancer Institute Common
Terminology Criteria (Version 3, March 2003).
Biopsy procedure and tissue handling
All buccal biopsies were performed under aseptic conditions by, or
under the direct supervision of, a consultant on the UK specialist
list for Oral Medicine. After local anaesthesia was achieved with
approximately 1 ml of 2% lidocaine with 1 : 80 000 epinephrine
(AstraZeneca, Macclesfield, UK), a 3 mm biopsy punch (Stiefel
Laboratories Limited, Buckinghamshire, UK) was used to obtain a
core from the buccal mucosa of either the left or right cheek near
the level of the occlusal line, and then immersed in 10% neutral-
buffered formalin. When multiple biopsies were obtained, all four
quadrants of the mouth were utilised, with the order of location
of the four biopsies in each subject (front/back, left/right)
being randomly determined at the commencement of their entry
into the study.
IHC and signal quantification
Following a uniform fixation period of as close to 48 h as possible,
the biopsy specimens were embedded in paraffin. Serial sections
(4mm) were cut, and dried on slides at 371C overnight.
Dewaxed sections were subjected to heat-induced epitope
retrieval in a microwave pressure cooker containing 0.01 M citrate
buffer, pH 6.0 for 2 min at 1201C.
Immunohistochemistry staining was performed using a Lab
Vision Autostainer (Lab Vision [UK] Ltd, Newmarket, UK).
Endogenous hydrogen peroxidase activity was quenched by
incubation in 3% aqueous H2O2 for 10 min, followed by a 20 min
incubation in serum-free protein block (X0909, DakoCytomation
Ltd., Ely, Cambridgeshire, UK). Primary antibody, diluted in tris-
buffered saline with 0.1% Tween 20, was applied for 60 min.
Detection was achieved using Dako’s EnvisionþHorse Radish
Peroxidase-labelled polymer system (K4007 for mouse primary
antibodies, K4011 for rabbit primary antibodies) with 3,3
diaminobenzidine tetrahydrochloride as the chromogen (Dako-
Cytomation Ltd, Ely, Cambridgeshire, UK). All incubations were at
room temperature, and sections were washed thoroughly in tris-
buffered saline between each step. Sections were counterstained
with Carazzi’s haematoxylin before being dehydrated, cleared and
mounted in Histomounts (Raymond A Lamb Ltd, Eastbourne,
UK). Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) for the detection of apoptotic cells was
performed according to the kit (Roche Diagnostics GmbH,
Penzberg, Germany) using the Ventana Discovery platform
(Ventana Medical Systems S.A., Illkirch Cedex, France). Details
of the antibodies and techniques used for each marker are shown
in Table 1.
Sections from previously characterised xenografts were used as
positive controls. Suitable isotype/Ig fractions were used to stain
negative control buccal biopsy sections. Antibodies were validated
by preadsorption of the antiserum with the peptide antigen used to
generate the antibody, where available, looking for complete
ablation of any antibody-binding signal. Phospho-specific anti-
bodies were further appraised by looking for complete signal
abolition following pre-incubation of sections with alkaline
phosphatase (713 023 Roche Diagnostics GmbH, Penzberg,
Germany).
Image analysis and quantification was performed with the Zeiss
KS400 system (Imaging Associates, Bicester, Oxfordshire, UK)
using a bespoke macro programme linked to a Leica DMRB
microscope. Care was taken not to overlap fields of view to ensure
that cells were not counted twice. The number of positive nuclei
was expressed per mm of basement membrane (BM) as a unit
length labelling index (ULLI) (Monticello et al, 1990).
Statistical analysis
Biomarker data were log-transformed prior to analysis and
compared to untransformed data. The intersubject variability of
Table 1 Details of antibodies/techniques used
Target Supplier Host/type Catalogue number Dilution Detection System
Total-pRb CST Mouse monoclonal 9309 1 : 100 Mouse Envision+
Phospho(S249/T252)-pRb Biosource Rabbit polyclonal 44-584 1 : 1000 Rabbit Envision+
Total-p27 RDI Rabbit polyclonal P27CabrX 1 : 100 Rabbit Envision+
Phospho(T187)-p27 Upstate Rabbit polyclonal 06-996 1 : 100 Rabbit Envision+
p53 NovoCastra Rabbit polyclonal NCL-p53-CM1 1 : 2500 Rabbit Envision+
Cyclin A Neomarkers Mouse monoclonal MS-1061S1 1 : 40 Mouse Envision+
Cyclin E NovoCastra Mouse monoclonal NCL-CYCLIN E 1 : 20 Mouse Envision+
Ki67 Dako Mouse monoclonal M7240 1 : 25 Mouse Envision+
Phospho(S10)-Histone H3 Upstate Rabbit polyclonal 06–570 1 : 1000 Rabbit Envision+
p21 BD Pharmingen Mouse monoclonal 610234 1 : 25 Mouse Envision+
Cleaved-Caspase-3 CST Rabbit polyclonal 9661 1 : 300 Rabbit Envision+
M30 Roche Mouse monoclonal 2 140 349 1 : 200 Mouse Envision+
TUNEL (in situ cell death kit) Roche N/A 1 684 817
pRb¼ phosphorylated pRb; phospho-p27¼ phosphorylated p27; TUNEL¼ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. CST–New England
Biolabs (UK) Ltd, Hitchin, Hertfordshire, UK; Biosource –B-1400 Nivelles, Belgium; RDI–Concord MA 01742-3049 USA; Upstate –Dundee, UK; Novocastra –Newcastle upon
Tyne, UK; Neomarkers–Lab Vision (UK) Ltd, Newmarket, Suffolk, UK; Dako–Ely, Cambridgeshire, UK; BD Pharmingen –Cowley, Oxford, UK.
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those IHC markers that were assessed within Study A but not
within Study B was calculated. Coefficient of variation (CV) was
calculated as square root (e(s2)1) 100%, where s was the
standard deviation (s.d.) of the log-transformed data.
The primary objective of Study B was to assess the intrasubject
variability of total retinoblastoma protein (pRb), phosphorylated
pRb (phospho-pRb), total p27 and phosphorylated p27 (phospho-
p27). The secondary objectives of Study B were to assess the
intersubject variability, the evidence for any effect of biopsy site
or of nominal or actual biopsy time on these marker levels; and
to assess the relationship between total and phospho-pRb, and
between total and phospho-p27, as ratios. Components of variation
were estimated from an analysis of variance (ANOVA) model,
using an F-test calculated from proc mixed within SAS. The models
constructed allowed for the effects of nominal time, actual time
and subject. Times were fitted as fixed effects, with subjects fitted
as random effects. Statistical significance was assumed to be when
Po0.05.
No inferential statistical analyses were undertaken on data from
the tolerability assessments in Studies A or B.
RESULTS
The mean ages of the volunteers in Studies A and B were 45.3 and
42.6 years, respectively. Each biopsy procedure took between 10
and 20 min. Actual biopsy times varied by as much as 90 min for
the same nominal time point between individuals. A suture passed
through the base of the biopsy pedicle prior to devascularisation
(Figure 1) was found to facilitate handling of the specimen and
minimise crush artefact. In addition, the hole left by the suture
assisted in the orientation of the specimen during subsequent
analyses.
Tolerability and adverse events
The specific questions asked, and the answers that the subjects
gave, relating to overall tolerability in terms of their willingness to
undergo repeat biopsies, based on their actual and hypothetical
experiences in Study A, are presented in Table 2.
In Study B, based on their actual experiences of four biopsies in
24 h, all 12 subjects answered ‘YES’ to the overall tolerability
question: ‘Would you undergo the same procedure again?’
The adverse events recorded during Studies A and B, considered
causally related to the study procedures, are presented in Table 3.
Feasibility of detecting proliferation and apoptosis
markers in buccal mucosa
Signals detectable on IHC in buccal biopsies compatible with the
expected patterns of cellular staining were obtained for Ki67, total
pRb, phospho-pRb, total p27, phospho-p27, Cyclin E, p21, p53,
phosphorylated-histone H3 (phospho-HH3) and Cyclin A (Figure
2A– J). The apoptotic markers M30 and cleaved caspase 3 worked
well in control xenograft tissue, but produced no detectable signals
in the buccal mucosa. Signals were obtained in buccal mucosa with
TUNEL, but this technique appeared relatively insensitive to
apoptosis in our hands, failing to detect some overtly apoptosing
cells (data not shown).
Components of variability
Multiple, stepped sections (X every fifth section) from each biopsy
in Study A were stained and analysed to determine the optimum
number of sections required for each marker. Since stepped
sections were employed, with an interval of at least 16 mm, a single
cell was not counted more than once, in effect increasing the length
of buccal mucosa measured for each marker. The optimum
number of sections was assumed to be where the graph of CV
plotted against the number of sections leveled out, that is, the point
beyond which increasing the number of sections did not reduce
the variability further. For markers exhibiting relatively high levels
of expression, such as phospho-pRb, only five sections needed to
be measured before the variability plateaued, but for a marker
exhibiting a lower relative frequency of expression, such as
phospho-histone H3, the number of sections required increased to
11 (Figure 3). For reasons of practicality, five stepped sections were
quantified for all markers within Studies A and B.
Table 3 Adverse events considered to be related to study procedures, by arbitrary subject number, from the single and multiple buccal biopsy studies
Subject Onset Adverse event Duration (min) Maximum CTC grade Intervention
1 (Study A) Immediately after biopsy procedure Dizziness 5 1
1 (Study A) Immediately after biopsy procedure Biopsy site discomfort 30 1 Paracetamol (same day only)
2 (Study A) Immediately after biopsy procedure Feeling hot/abnormal 2 1
3 (Study B) 3 h, 26 min after third biopsy procedure Bleeding biopsy site 20 1
3 (Study B) 3 h, 26 min after third biopsy procedure Biopsy site discomfort 45 1 Paracetamol (same day only)
Figure 1 Human buccal biopsy (3 mm), postfixation, with suture in situ
for ease of handling.
Table 2 Tolerability assessment responses from single buccal biopsy
study
Tolerability question
Response
(% affirmative)
Would you have the same procedure done again? 100
Would you have, in theory, six biopsies in a day? 80
Would you have, in theory, three biopsies in a day? 90
Would you have, in theory, six biopsies (consecutive days) 90
Would you have, in theory, six biopsies (consecutive weeks) 100
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Exploration of the data for all transformed markers revealed
them to be log-normally distributed. Quantitative scores were
generated from the biopsies within Study A for the following
markers: total pRb, phospho-pRb, total p27, phospho-p27,
phospho-HH3, p21, p53, Cyclin A, Cyclin E, Ki67 and TUNEL.
The summary statistics for the markers that were not assessed
further in Study B are presented in Table 4. For those markers with
low signal levels, the estimates of variability could well be
improved upon if more sections per block had been counted.
In Study B, four markers (total pRb, phospho-pRb, total p27 and
phospho-p27) were quantified to allow components of variability
to be addressed in detail. With the exception of total pRb, sections
were quantified from each of the 12 subjects in Study B. In three
subjects, it was found that the staining for total pRb was punctate,
intense and extranuclear. The reason for this deviation from the
normally accepted nuclear pattern of staining was unknown, but
the data on total pRb from these three subjects in Study B were not
included in the subsequent analysis.
There was no discernible pattern of biopsy site within the oral
cavity (front/back, left/right) on visual inspection of the group
geometric mean expression levels of these markers (Figure 4A–D),
or within individuals (data not shown). There was also no
statistically significant effect (P40.05) on either the group
geometric mean expression levels of nominal biopsy time (Table 5)
or of actual time (data not shown), or of a consistently discernible
pattern within individuals indicating an effect of nominal biopsy
time (Figure 5A–D) or of actual time (data not shown). The
ANOVA model selected allowed for the effects of nominal time and
subject. The effect of actual time was also considered initially, but
was not included in the final ANOVA model as there was no
evidence of such an effect.
DISCUSSION
Pharmacodynamic markers of drug action derived from easily
accessible normal human tissue could assist clinical drug
development. The buccal mucosa is one such easily accessible
normal tissue. Buccal mucosa-derived cells may be procured
through exfoliation by scraping or brushing, or through removal of
solid tissue specimens by incisional or punch biopsies (Epstein
et al, 2002; Oliver et al, 2004). Exfoliated buccal squames are easier
to acquire but are predominantly derived from the superficial cell
layers. As the buccal mucosa is a stratified epithelium with the
majority of proliferating cells being present in the layers at, or near
to, the BM (cf Figure 2), standard exfoliative techniques, which do
A B C
D E F
G
J
H I
Figure 2 Representative sections of buccal biopsy tissues stained for (A) Ki67, (B) total pRb, (C) phospho-pRb, (D) total p27, (E) phospho-p27, (F)
cyclin A, (G) p21, (H) p53, (I) phospho-HH3 and (J) cyclin E. The solid horizontal line on each picture represents a scale of 100 mm.
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not sample from these deeper layers, may limit the usefulness of
this approach for assessing PD end points based on inhibition of
proliferation. Sampling the full thickness of the mucosa, punch
biopsies, offer advantages over incisional biopsies in terms of
simplicity, speed, cost and safety (Lynch and Morris, 1990). They
also offer size uniformity, which may be important in standardi-
sing both the speed of tissue penetration by fixative and the
chances of observing rare cellular events.
In studies A and B, single and multiple 3 mm punch biopsies of
the buccal mucosa were well tolerated with minimal procedure-
related adverse events (Tables 2 and 3), implying that multiple PD
assessments over hours as well as days within the same individual
would be practicable with these techniques.
To generate meaningful quantitative data for PD assessments,
we attempted to optimise and standardise our methods for tissue
preparation, IHC and analysis. Our optimised protocol was
inevitably a compromise between the requirements of each
biomarker and, for key biomarkers in intervention studies in the
future, it may be necessary to have marker-specific protocols for
tissue preparation and analysis, rather than to adopt a ‘one size fits
all’ approach.
Our quantitative IHC revealed a wide range of expression levels
between different markers in the buccal mucosa (Tables 4 and 5).
In general, proliferation markers with a very low level of
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Figure 3 Effect of number of stepped sections counted per block on the
variability of marker expression. Each histogram represents the CV derived
from the expression levels of (A) phospho-pRb and (B) phospho-HH3
based on sampling from 2 to 9 and 2 to 15 serial sections, respectively, of
buccal biopsy tissue.
Table 4 Immunohistochemistry marker quantification in healthy human
buccal mucosa (Study A)
Marker
Geometric
meana CV (%)a Minimum Maximum
Phospho-HH3 2.14 76.87 0 7.94
p21 42.84 100.44 9.35 126.47
p53 6.74 167.9 0 32.88
Cyclin A 29.53 43.92 12.58 57.33
Cyclin E 55.18 41.93 28.14 86.88
Ki67 37.23 161.45 2.5 108.21
TUNEL 6.67 126.28 0.89 18.29
aWhen calculating the geometric means and coefficients of variation (CVs) for
phospho-HH3 and for p53, because the minimum values for both were zero, the
limit of quantitation of the ULLI assay (1.0) was used as the minimum value.
TUNEL¼ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labelling.
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Figure 4 Lack of effect of anatomical site of buccal biopsy on expression
levels of markers (A) total pRb (n¼ 9), (B) phospho-pRb (n¼ 12), (C)
total p27 (n¼ 12), (D) phospho-p27 (n¼ 12). Solid symbols (’)
represent the geometric means in buccal biopsies taken from either the
front-left, front-right, back-left or back-right regions of the oral cavity. Open
symbols (&) represent the maxima and minima associated with the same
markers at each anatomical site.
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expression are unlikely to be useful as end points in antiproli-
ferative drug studies as the anticipated effect of these drugs would
be to make such low levels even lower. In contrast, markers of cell-
cycle arrest, such as p27, may be expected to increase in the
presence of these drugs (Malik et al, 2003). Apoptosis, which could
also conceivably increase with certain interventions, is such a rare
event in the normal buccal mucosa that its usefulness as a potential
PD marker is uncertain (Hirota et al, 2002; Loro et al, 2002; Hague
et al, 2004).
Progression through the cell cycle can be monitored by
assessing levels of pRb and p27 in both their un/hypophos-
phorylated (pRb and p27), and hyperphosphorylated (phospho-
pRb and phospho-p27) states (Buchkovich et al, 1989; Vlach et al,
1997; Howard et al, 2000). Antibodies directed against total pRb or
total p27 are likely to detect both the hyper- and hypo/non-
phosphorylated forms of the protein (Buchkovich et al, 1989).
Elevated levels of p27 induces G1 arrest (Sherr, 2000). To permit
hyperphosphorylation of pRb and cell-cycle progression, the
inhibitory influence of p27 is removed through hyperphosphory-
lation, ubiquitination and destruction within the proteasome
(Vlach et al, 1997; Israels and Israels, 2000). Owing to the high
signal levels of total pRb, phospho-pRb, p27 and phospho-p27
found in the buccal mucosa in Study A, and the fact that the
expression and activation of these cell-cycle proteins appeared
relatively tightly controlled, with the nuclear signal being largely
‘on or off’ (Figure 2B–E) allowing easier automated counting, we
chose to explore these markers in more detail in Study B. In
addition, there appeared to be an inverse relationship in the
expression/activation levels of these proliferation and cell-cycle
arrest markers, particularly between total pRb and total p27
(Figures 2B and D). If such ‘mirror image’ signals changed on
intervention in opposite but appropriate directions, this would
significantly increase an investigator’s confidence in attributing
any such changes to antiproliferative mechanisms of action
(Daneshmand et al, 2003). The basal cell layers in which the
highest levels of total pRb are seen are also the most actively
proliferating, so the total pRb antibody is likely to be detecting
cells that have a preponderance of pRb in the hyperphosphorylated
state. This is confirmed by the observation that higher levels of
phospho-pRb are apparent within the basal cells, compared to the
suprabasal cells (Figure 2C). Total pRb levels have not been
reported to change significantly throughout the cell cycle in vitro
(Buchkovich et al, 1989), but the marked differences in total pRb
expression levels observed between basal and suprabasal cells
suggests either this does not hold true for the human buccal
Table 5 IHC marker quantification by nominal time point in healthy
human buccal mucosa (Study B)
Marker
Nominal
time (h)
Geometric
mean Minimum Maximum 95% CI
Total pRb 0 360.18 278.88 505.32 308.8–420.1
4 338.41 240.6 553.2 290.2–394.7
8 377.02 293.24 472.12 323.2–439.7
24 343.48 257.6 531.28 294.5–400.6
Phospho-pRb 0 396.46 190.92 680.74 324.5–484.4
4 347.91 195.52 649.32 284.7–425.1
8 374.65 214.47 793.72 306.6–457.8
24 355.79 169.50 601.75 291.2–434.7
Total p27 0 300.19 205.46 414.06 251.6–358.1
4 311.88 187.14 52.42 261.4–372.2
8 278.14 168.4 509.41 233.1–331.8
24 262.44 157.11 532.21 220.0–313.1
Phospho-p27 0 421.26 257.51 612.21 374.3–487.1
4 444.01 238.09 643.44 384.0–513.4
8 462.34 277.79 611.24 399.8–534.6
24 405.41 268.02 572.69 350.6–468.8
Phospho-pRb¼ phosphorylated pRb; phospho-p27¼ phosphorylated p27.
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Figure 5 Lack of effect of nominal time of buccal biopsy on expression
levels of markers (A) total pRb (n¼ 9), (B) phospho-pRb (n¼ 12), (C)
total p27 (n¼ 12), (D) phospho-p27 (n¼ 12), taken from each subject at
nominal times of 0, 4, 8 and 12 h.
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mucosa in vivo, or that these are not reflecting cell-cycle
differences per se, but some effect of cellular differentiation as
the cells migrate up through the stratified buccal epithelium.
Evidence of circadian rhythms in the normal buccal mucosa has
been reported for several different proliferation markers, based on
the degree to which data from six biopsies taken over 24 h could be
fitted to cosine curves (Bjarnason et al, 1999). We found no
evidence of such an effect for the markers analysed with respect to
time in Study B (Figure 5; Table 5). Either circadian influences
do not extend to the markers we used, or if they do exist, given
that they would be contained within our estimates of intrasubject
variability, their contribution is sufficiently low as to not be
significant.
The high signal and low CV of the four markers analysed in
Study B (Table 6) make them attractive end points for use in
studies that involve drugs affecting these pathways. The informa-
tion in Table 6 could be used to adequately size either a parallel
arm or crossover study, based on estimates of the expected drug
effect and the statistical power required to detect such an effect.
Ratios of phospho/total pRb or p27, when compared to either the
total- or phospho-marker levels alone, did not appear to
consistently improve either the intra- or inter-subject CVs for
these markers (Table 6). Similarly, the ratios did not reveal any
novel patterns in marker expression when analysed by group or
individual for either biopsy site or nominal biopsy time effects,
compared to the total- or phospho-marker levels alone (data not
shown). This may reflect the fact that the antibodies used to detect
the total forms of each protein have different binding affinities and
potentially different numbers of epitopes compared to the
antibodies directed against the hyperphosphorylated forms.
Consequently, the total and phospho-signal levels generated by
these antibodies for p27 and pRb may not follow a simple linear
relationship.
Having established the feasibility and variability of detecting
signals for a range of different IHC markers within the buccal
mucosa, the next step must be to assess the effect of an
antiproliferative drug, or a drug working directly on the pathways
that involve these markers, on their expression levels. While it is
impossible to state that marker levels and biopsy tolerability in
male volunteers will be directly extrapolatable to female subjects or
to patients, we believe these data offer a reasonable base from
which to start. Evidence of an effect, particularly if supported by
opposing changes in proliferation and cell-cycle arrest markers,
would act as initial corroboration of the normal tissue-based
biomarker approach to proof of drug mechanism and dose/
schedule finding described in the introduction to this paper.
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